HIT Consultant December 23, 2025
What You Should Know:
– Vyriad, Inc. has secured the final $25M of its Series B financing, bringing the total round to $85M led by Mr. Harry Stine of Stine Seed Farms, Inc.
– The funding will power the first-in-human trials of VV169, an in vivo CAR-T therapy for multiple myeloma that modifies immune cells directly inside the patient’s body. This approach eliminates the complex, expensive lab manufacturing required by current CAR-T treatments, potentially offering a scalable, “off-the-shelf” cure via a single intravenous injection.
The “In Vivo” Revolution: No Lab Required
Current “ex vivo” CAR-T therapies are bespoke and labor-intensive. They require a personalized manufacturing slot for every single patient, leading to bottlenecks that leave desperate patients waiting weeks or...
Today's Sponsors
Today's Sponsor